SMS Pharmaceuticals has announced a significant corporate restructuring move, increasing its ownership stake in SMS Peptides to 99.99% through a new share issuance. This strategic transaction strengthens the pharmaceutical company's control over its subsidiary operations and represents a substantial consolidation of the company's peptides business under direct control. The increased ownership structure provides SMS Pharmaceuticals with enhanced operational control and streamlined decision-making capabilities within its peptides division.
The share issuance transaction method has resulted in SMS Pharmaceuticals achieving near-complete ownership of SMS Peptides. This consolidation aligns with corporate governance practices aimed at optimizing subsidiary management and operational efficiency. The move demonstrates the company's proactive approach to organizational development and commitment to strengthening its market position in the pharmaceutical industry.
According to recent data, SMS Pharmaceuticals has shown strong market performance with +30.67% returns over 1 year and +164.16% returns over 5 years. The company has been actively expanding its operational capabilities, including the recent formation of SMSco Lab Pvt Ltd as a new subsidiary. Recent developments also include successful USFDA inspections at the company's Vizag API facility and strong quarterly results with 80% YoY PAT growth in Q2FY26 driven by backward integration strategies.
